Peer-reviewed veterinary case report
Autoantibodies help early diagnosis and monitoring of cat mammary
By El-Rasikh, Asmaa M et al.·Published in Scientific reports·2021·Department of Microbiology·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The implication of autoantibodies in early diagnosis and monitoring of plasmonic photothermal therapy in the treatment of feline mammary carcinoma.
- Species:
- cat
Plain-English summary
A cat with mammary cancer was treated with a new therapy called Plasmonic Photothermal Therapy (PPTT), which uses heat to target tumor cells. Researchers found that this treatment significantly lowered certain immune markers (autoantibodies) linked to the cancer, indicating it may help in monitoring the disease. In contrast, traditional surgery alone or a combination of surgery and PPTT did not have the same effect on these markers. This suggests that PPTT could be a promising option for managing feline mammary carcinoma and tracking its progression.
People also search for: cat mammary cancer treatment · Plasmonic Photothermal Therapy for cats · feline cancer autoantibodies
Abstract
Feline mammary carcinoma (FMC) shows great similarities to human breast cancer in the cellular and molecular levels. So, in cats as in humans, the role of immune responses is indicated to detect and follow up the development of tumors. As a new breast cancer therapeutic approach, Plasmonic Photothermal Therapy (PPTT) is an effective localized treatment for canine and feline mammary-carcinoma. Its systemic effect has not been inquired yet and needs many studies to hypothesis how the PPTT eradicates tumor cells. In this study, it is the first time to detect (P53, PCNA, MUC-1, and C-MYC) feline autoantibodies (AAbs), study the relationship between PCNA AAbs and mammary-tumors, and investigate the effect of PPTT on the humoral immune response of cats with mammary-carcinoma through detection of AAbs level before, during, and after the treatment. The four-AAbs panel was evaluated in serum of normal and clinically diagnosed cats with mammary tumors using Enzyme-Linked Immunosorbent Assay. The panel showed 100% specificity and 93.7% sensitivity to mammary tumors. The panel was evaluated in PPTT monotherapy, mastectomy monotherapy, and combination therapy. PPTT monotherapy decreased AAbs level significantly while mastectomy monotherapy and combination therapy had a nonsignificant effect on AAbs level.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34001936/